Neon Therapeutics makes one last retreat, selling itself cheap in a bargain basement M&A deal
Crushed by weak data for what had been their lead drug, Neon Therapeutics is being bought for parts this morning.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 102,100+ biopharma pros reading Endpoints daily — and it's free.